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Abstract
Background: Increasing numbers of healthy individuals are undergoing predispositional personal genome
sequencing. Here we describe the design and early outcomes of the PeopleSeq Consortium, a multi-cohort
collaboration of predispositional genome sequencing projects, which is examining the medical, behavioral, and
economic outcomes of returning genomic sequencing information to healthy individuals.
Methods: Apparently healthy adults who participated in four of the sequencing projects in the Consortium were
included. Web-based surveys were administered before and after genomic results disclosure, or in some cases only
after results disclosure. Surveys inquired about sociodemographic characteristics, motivations and concerns, behavioral
and medical responses to sequencing results, and perceived utility.
Results: Among 1395 eligible individuals, 658 enrolled in the Consortium when contacted and 543 have completed a
survey after receiving their genomic results thus far (mean age 53.0 years, 61.4% male, 91.7% white, 95.5% college
graduates). Most participants (98.1%) were motivated to undergo sequencing because of curiosity about their genetic
make-up. The most commonly reported concerns prior to pursuing sequencing included how well the results would
predict future risk (59.2%) and the complexity of genetic variant interpretation (56.8%), while 47.8% of participants were
concerned about the privacy of their genetic information. Half of participants reported discussing their genomic results
with a healthcare provider during a median of 8.0 months after receiving the results; 13.5% reported making an
additional appointment with a healthcare provider specifically because of their results. Few participants (< 10%)
reported making changes to their diet, exercise habits, or insurance coverage because of their results. Many
participants (39.5%) reported learning something new to improve their health that they did not know before.
Reporting regret or harm from the decision to undergo sequencing was rare (< 3.0%).
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Conclusions: Healthy individuals who underwent predispositional sequencing expressed some concern around
privacy prior to pursuing sequencing, but were enthusiastic about their experience and not distressed by their results.
While reporting value in their health-related results, few participants reported making medical or lifestyle changes.
Keywords: Personal genome sequencing, Return of results, Genomics, Test utility, Public health
Background
Whole genome and exome sequencing have well-estab-
lished clinical utility for rare disease diagnosis [1, 2] and
personalized cancer treatment [3]. Driven by decreasing
costs, sequencing is increasingly being used in other clin-
ical, research, and commercial settings, including as a
screening tool in apparently healthy individuals, termed
predispositional personal genome sequencing (PPGS) [4].
Individuals pursuing PPGS are not using genome sequen-
cing for diagnostic purposes, but nonetheless are interested
in obtaining health-related results. For many participants
and providers, there is an expectation that PPGS will even-
tually enable a more personalized and preventive approach
to medicine, in which illness is anticipated or prevented
through screening for genetic predispositions to disease
[5]. However, the actual clinical utility in healthy individ-
uals is unknown, and the risks, benefits, and costs both to
the individual and society are unclear [6, 7]. Despite this
uncertainty, there are increasing numbers of PPGS projects
underway, both research- and industry-based [4].
Unlike screening tests that detect early signs of disease,
PPGS screens for a potential predisposition to disease. Of
particular concern are individuals who will be falsely iden-
tified as being at risk [6, 7] as a result of analytic errors, in-
terpretation errors, and/or gaps in understanding of the
penetrance of each variant, especially in the absence of
family history of the condition [8]. These factors may
present challenges for clinical management, which in turn,
could create unnecessary anxiety and medical surveillance,
and drive increased healthcare expenditures [9]. Previous
and ongoing PPGS studies have reported numerous exam-
ples of successful predispositional identification of individ-
uals with disease or increased disease risk [10, 11]. Recent
reports show that as many as 20% of participants in pre-
dispositional sequencing cohorts may have a variant with
monogenic disease risk [12–14]. At this early stage, how-
ever, the precise fraction of individuals who might benefit
from sequencing due to disease prevention or early diag-
nosis is uncertain.
Multiple research studies have sought to improve our
understanding of the possible clinical and personal util-
ity of PPGS. The Harvard Personal Genome Project
(PGP), launched in 2005, was arguably the first PPGS
project, though the return of genomic results and the
consequences thereof were not the main purpose [15].
More recent studies, conducted mostly as controlled re-
search protocols in clinical settings, have explored the
reactions to sequencing and the return of results to
healthy individuals [11, 16–23]. For example, within
Geisinger, an integrated healthcare system, there are
plans for over 250,000 patient-participants to have their
exomes sequenced, most without a specific indication,
under the MyCode® Community Health Initiative, an ex-
pansive clinical research protocol [21]. The All of Us Re-
search Program, part of the Precision Medicine Initiative
(PMI), has publicly committed to providing participants
access to the data gathered, which might include gen-
omic information, although the details have not yet been
finalized [24]. Multiple biotech companies have launched
or announced broad physician-ordered predispositional
sequencing panels [25–28] and more consumer-oriented
research products [29–32]. These developments reflect
the multiple forces, such as changing views on obliga-
tions to return study results to participants, disinter-
mediation of traditional medical authorities, and
large-scale sequencing efforts seeking pharmaceutical
targets, which are accelerating the availability of PPGS.
The Personal Genome Sequencing Outcomes (People-
Seq) Consortium is a collaborative effort among multiple
academic and commercial PPGS projects designed to
cost-effectively collect coherent survey data on the short-
and long-term outcomes of apparently healthy individuals
already undergoing sequencing through one of the Con-
sortium projects. Thus far, the Consortium has enrolled
individuals across four PPGS projects who have received a
broad range of health-related genomic results from per-
sonal genome or exome sequencing. Additional sites are
in the process of joining the Consortium, representing a
range of both research and commercial sequencing pro-
viders. This Consortium then provides a mechanism to
examine the outcomes of PPGS in the many different con-
texts in which this technology is now employed. People-
Seq participants are innovators and early adopters [33],
similar to initial users of other rapidly evolving technolo-
gies. Studying PPGS early adopters can provide valuable
insights because these individuals have actually used these
technologies, and thus can provide concrete evidence of
both the risks and benefits [34]. Here we describe the de-
sign of the PeopleSeq Consortium and present descriptive
findings from the four initial projects.
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Methods
Overview
The PeopleSeq Consortium, formed in 2014, is a collabor-
ation of PPGS projects designed to study participants’ mo-
tivations and experiences and the self-reported medical,
behavioral, and economic outcomes of PPGS. Here we re-
port on data collected from participants in the first four
projects to contribute to the Consortium: the Harvard
PGP [15], the Baylor College of Medicine’s Young Presi-
dents’ Organization (YPO) and MD/PhD Genome Pro-
jects [17], Mt. Sinai’s HealthSeq project [19], and
Illumina’s Understand Your Genome (UYG) program
[35]. All of the projects performed genome or exome se-
quencing on apparently healthy adults and returned a re-
port of the individual genomic results back to participants.
The consent, genetic counseling, and results disclosure
processes varied by project (see Additional file 1: Table S1
for an overview of each project and Linderman et al. [4]
for a more detailed review of these and similar projects).
Clinical genome reports from a CLIA (Clinical Laboratory
Improvement Amendments)-certified laboratory were
only provided by UYG. UYG was also the only project to
send a clinical report to a healthcare provider, while PGP
publicly shared participants’ genomes online. Though the
type of PPGS results varied by project, all of the projects
returned monogenic disease findings in numerous genes
(more than the genes specified in the American College of
Genetics and Genomics recommendations for reporting
of secondary findings) [36, 37]. The PeopleSeq Consor-
tium itself did not perform sequencing of participants but
administered common web-based surveys to participants
in the collaborating projects. Consent for participation to
receive surveys from the PeopleSeq Consortium was en-
tirely separate from consent in the original PPGS project.
Depending on the site and timing of the invitation, par-
ticipants were invited to enroll and complete PeopleSeq
surveys either before or after disclosure of their genomic
results. Those who enrolled into the PeopleSeq Consor-
tium after disclosure of their PPGS results received one ini-
tial survey (the “catch-up” survey), while those who
enrolled before disclosure of their PPGS results received
two surveys: a survey after signing up for PPGS but before
disclosure of their PPGS results (the pre-disclosure survey)
and after disclosure (the post-disclosure survey). At the
Consortium’s conception, all participants received the
catch-up survey; however, since November 2015, the pre-
and post-disclosure surveys were administered whenever
possible. All participants received annual follow-up sur-
veys. This longitudinal design allows for assessment of
both short- and long-term outcomes. The Partners Health-
Care Human Research Committee and the Baylor College
of Medicine Institutional Review Board approved the entire
study. Each site consulted their Institutional Review Board,
as applicable, and received additional approval if necessary.
Survey design and measures
The PeopleSeq Consortium surveys were developed by an
interdisciplinary team of geneticists, genetic counselors,
ethicists, psychologists, and survey design researchers.
The surveys were adapted from the Impact of Personal
Genomics (PGen) Study surveys [38], developed using ex-
pert consultation and cognitive interview techniques, with
additional questions derived from qualitative interviews in
the MedSeq Project [18]. The survey questions assessed
sociodemographic characteristics, personal and family
health information, prior use of genetic testing, motiva-
tions and concerns, psychological impacts, risk percep-
tions, perceived utility and harms, and behavioral and
medical responses (see Additional file 1: Table S2 for a
summary of the survey measures and Additional file 2 for
copies of the study surveys). Where possible, the surveys
utilized validated measures of psychological states [39–41]
and decision regret [42], as well as published scales for
genomics self-efficacy [43], genome sequencing knowledge
[44], and other measures [45].
Genome sequencing knowledge was evaluated using
an 11-item assessment with 5-level Likert scale re-
sponses (strongly disagree to strongly agree) [44]. Re-
sponses for negatively worded items were reversed to
make “strongly agree” the correct response for all items.
Decision regret was measured with a 5-item instrument
with a 5-level Likert scale used for agreement with each
item (scored 1–5 points) [42]. The mean score across
items was calculated and then converted to a total score
out of 100 with higher scores indicating greater regret.
Some survey questions were tailored to each project to
reflect differences in the participant experience. For ex-
ample, questions were populated with site-specific
names and some questions only included response op-
tions corresponding to the genomic results provided by
that project. Following continued analysis of preliminary
data, the surveys have been revised over time, refining
the wording of some of the questions that were not part
of validated measures and adding or deleting questions
as necessary. While this refinement has improved com-
prehension and shortened the surveys, these changes
have resulted in some missing data for early participants.
Participant recruitment and data collection
The PeopleSeq Consortium recruited adults aged 18
years or older who independently decided to pursue
PPGS through one of the collaborating projects and,
when required by the collaborating project, consented to
be contacted about related research projects. All eligible
individuals who were previously enrolled in PGP, Health-
Seq, and the YPO and MD/PhD Genome Projects re-
ceived an invitation to participate in the Consortium via
email with a description of the study and a link directing
them to the web-based survey. Potential participants
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from UYG were initially approached in person, by email,
or via announcement at a UYG program event before
receiving the PeopleSeq invitation email.
The invitation email to complete the catch-up survey
was sent at least 2months after receipt of PPGS results.
For participants enrolled prior to their PPGS results dis-
closure, an email invitation to complete the pre-disclosure
survey was sent 1 to 3months before disclosure of gen-
omic results, and the post-disclosure survey was sent 2 to
3months after receipt of their genomic results. The timing
of these emails was coordinated between the collaborating
site and SoundRocket (Ann Arbor, MI). If a participant
did not complete the pre-disclosure survey prior to receiv-
ing their PPGS results, an invitation to complete the
catch-up survey was sent. If, at the start of the
post-disclosure or catch-up survey, a participant indicated
that they had not viewed their PPGS results, they were
not permitted to complete the survey until they had done
so. Participants were invited to complete an annual
follow-up survey. To improve the response rate, each sur-
vey invitation email was followed by up to four reminder
emails for nonresponders. Participants were also entered
into a random drawing to win an Apple Watch.
Informed consent was obtained electronically before
participants were given access to the initial study survey
(either the pre-disclosure or catch-up survey). The surveys
were administered on SoundRocket’s secure web-based
platform. Each participant was assigned a unique master
identifier, which allowed the participant to securely access
the survey system. Participants could freely navigate for-
ward and backward through the survey. All items in the
survey were optional and could be skipped. All responses
were saved, allowing for partially completed surveys and
permitting participants to complete the survey in multiple
sessions. At the end of the post-disclosure and catch-up
surveys, all participants (except for those from the YPO
and MD/PhD Genome Projects) were further asked to
consent to share their genomic results with the Consor-
tium. For those participants who consented to share their
results, the study coordinated with each collaborating site
to obtain this information. PGP participants were asked to
provide their PGP identifier linked to their already pub-
licly available genomic data.
Data analyses
The main analyses presented in this report were limited to
the 543 participants who completed the catch-up survey
or both the pre- and post-disclosure surveys and
responded to the referenced question. A comparison of
responders and nonresponders to the initial Consortium
invitation was conducted in a substudy of 1093 individuals
invited to participate from the two projects, PGP (352 in-
vitees) and UYG (741 invitees), for which case-level non-
responder demographic data were available (data limited
to age, gender, and race only). Chi-square tests were used
to assess demographic differences by response status.
In the main analyses, for participants completing both
the pre- and post-disclosure surveys, sociodemographic
characteristics, motivations and concerns when deciding
to pursue sequencing, and previous genetic testing were
reported on the pre-disclosure survey while all other data
were from the post-disclosure survey. Descriptive statistics
including means with standard deviations and counts with
percentages were computed for participant demographics,
psychological outcomes, downstream behavioral and
medical actions, perceived utility, and attitudes regarding
genome sequencing. Differences in sociodemographic
characteristics by project were compared by ANOVA for
continuous variables and chi-square or Fisher’s exact test
for categorical variables. Psychological, behavioral, and
medical responses, perceived utility, and attitudes were
compared by survey (pre-/post-disclosure surveys and
catch-up survey), given the differences in timing of survey
administration. To test differences by survey, the Wil-
coxon rank sum test was used for continuous and ordinal
measures and chi-square or Fisher’s exact tests were used
for categorical measures. Minimal statistically significant
differences were observed by survey (Additional file 1: Ta-
bles S3 and S4), so the results are presented for all surveys
combined. In an exploratory analysis, a sign test was used
to compare perceived present and future personal or clin-
ical utility of the genomic results. All statistical tests were
two-sided with p < 0.05 considered statistically significant.
The data were analyzed using SAS software (version 9.4;
SAS Institute, Cary, NC). The statistical code is available
from the authors upon request.
Results
A total of 1395 eligible individuals from four projects
were invited to participate in the PeopleSeq Consortium
between October 2014 and July 2017 (see Fig. 1 for an
Eligible for & Invited to 
PeopleSeq Consortium
n = 1,395
Consented & Enrolled 
in Consortium
n = 658
Catch-up Survey 
Completed
n = 419
Post-Disclosure 
Survey Completed
n = 124
Pre-disclosure Survey 
Completed
n = 239
Fig. 1 PeopleSeq Consortium enrollment and data collection
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enrollment flowchart and Additional file 1: Figure S1 for
a flowchart by project). A total of 658 individuals con-
sented and enrolled in the study for an initial response
rate of 47.2%. A total of 543 participants completed a
survey after receiving their genomic results (419 com-
pleted the catch-up survey and 124 completed both the
pre- and post-disclosure surveys), for a response rate of
38.9%. The post-disclosure survey is pending for 115
participants who either have received but not yet
returned the survey or have not yet received their se-
quencing results.
In a substudy of responders and nonresponders from
UYG and PGP in which case-level demographic nonre-
sponder data were available, the initial response rate was
30.7%. Females were overrepresented among the re-
sponders compared to nonresponders (39.6% versus
32.2%, respectively, p = 0.018; see Additional file 1: Figure
S2). There were borderline statistically significant differ-
ences in the distributions of race and age by response sta-
tus in which a higher percentage of white and younger
adults were responders, particularly for PGP.
The sociodemographic characteristics of the 543 par-
ticipants who completed a survey after receiving their
genomic results are summarized in Table 1. Nearly two
thirds of participants were male and most self-identified
as white. Almost all participants had at least a college
degree, and most participants had an annual household
income of $100,000 or greater. When asked about their
occupation, 29.1% reported that they were healthcare
professionals (including healthcare providers and clinical
researchers). Almost all participants described them-
selves as having good health or better; only 4.0%
self-reported fair or poor health. About half of partici-
pants reported receiving some form of personal genetic
testing prior to undergoing PPGS for this project. More
than 70% of these individuals reported using
direct-to-consumer (DTC) genetic testing (genotyping
rather than whole genome sequencing), and “curiosity
about health and traits predicted by my genetic
make-up” and ancestry were the most common reasons
for using DTC genetic testing. While there were statisti-
cally significant differences in the sociodemographic
characteristics across the four projects, participants in
each of the projects were predominantly older,
well-educated, wealthy, and in good health (Additional
file 1: Table S5).
Figure 2 presents the proportion of participants en-
dorsing each motivation for pursuing PPGS from a pro-
vided list. When asked what was the most important
factor in deciding to pursue PPGS, “curiosity about my
genetic make-up” and “interest in finding out about my
personal disease risk” ranked highest with about 15% of
participants endorsing each (data not shown). When
provided with a list of possible concerns when deciding
Table 1 Characteristics of participants with completed post-
disclosure or catch-up surveys in the PeopleSeq Consortium (n= 543)
Characteristic No. (%)a
Age, mean (± SD; range), years 53.0 (12.8;
22–91)
Gender
Female 202 (38.0)
Male 326 (61.4)
Other 3 (0.6)
Race
African American or Black 3 (0.6)
Asian 15 (2.8)
White 485 (91.7)
More than one race or other race 26 (4.9)
Hispanic or Latino 16 (3.0)
Education
Less than college degree 24 (4.5)
College degree 67 (12.7)
Some graduate school 160 (30.3)
Doctoral or professional degree 278 (52.6)
Annual income
< $40,000 36 (7.0)
$40,000–$99,999 82 (15.9)
≥ $100,000 397 (77.1)
Marital status
Married 383 (72.0)
Widowed, divorced, or separated 71 (13.4)
Never married 78 (14.7)
Biological children 370 (69.6)
US resident 469 (88.3)
Self-reported health
Excellent 167 (35.2)
Very good 210 (44.3)
Good 78 (16.5)
Fair 18 (3.8)
Poor 1 (0.2)
Prior genetic testing 247 (49.8)
Project
Illumina’s Understand Your Genome 329 (60.6)
The Harvard Personal Genome Project 167 (30.8)
Baylor Young Presidents’ Organization and MD/PhD
Genome Projects
28 (5.2)
Mount Sinai’s HealthSeq project 19 (3.5)
SD standard deviation
aPercentages may not sum to 100 due to rounding. Percentages and means
are not all based on total of 543 participants because of missing responses to
some survey items. The percent of missing responses ranges between 0 and
12.7% (median = 2.4% missing)
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to pursue PPGS, “how well the results would predict my
future risk” (59.2%) and “the complexity of genetic vari-
ant interpretation” (56.8%) were most frequently selected
as factors that participants were somewhat or very con-
cerned about (Fig. 2). Privacy of the genetic information
was a concern for 47.8% of participants, but only 12.8%
(range 2.5–22.2% across projects) of participants were
very concerned about privacy; this was lowest among
participants sequenced through PGP and ranged from
16.8% for UYG to 22.2% for the HealthSeq project par-
ticipants. Only 7.1% (range 3.1–11.1% across projects) of
participants were very concerned, while 26.4% (range
18.9–44.4% across projects) were somewhat concerned,
about the impact of the PPGS results on their ability to
obtain insurance. Strong concerns regarding insurance
discrimination were lowest among participants in PGP
and highest among participants in the HealthSeq
project.
The initial survey after PPGS results disclosure was
completed a median of 8.0 months after disclosure (15.2
months after disclosure for participants completing the
catch-up survey and 3.8 months for those completing
the post-disclosure survey). During this time, most par-
ticipants (86.8%) reported discussing their results with
someone; 81.1% of participants reported sharing their re-
sults with a family member (Table 2). Half (51.2%) of
participants reported discussing their PPGS results with
a healthcare provider, although fewer reported that they
had made (13.5%; range 10.6–16.7% across projects) or
planned to make (5.8%; range 0–6.9% across projects) an
additional appointment with a healthcare provider spe-
cifically because of their genomic results. Reporting dis-
cussion of the PPGS results with a provider was lowest
among PGP participants (41.2%) and highest among par-
ticipants in the YPO and MD/PhD Genome Projects
(79.2%). Of those participants discussing their results
with a provider, a primary care physician was the most
frequently cited type of provider consulted (81.1%),
followed by a genetics specialist (27.9%). The majority of
these individuals (81.8%) were somewhat or very satis-
fied with the discussion of their PPGS results with their
healthcare provider, while 6.2% reported that their
5%
14%
20%
25%
31%
37%
17%
43%
36%
46%
41%
19%
36%
22%
5%
11% 
10%
24%
33%
30%
56%
30%
39%
38%
44%
76%
60%
77%
0% 20% 40% 60% 80% 100% 
Other members of my family have had their genomes sequenced 
There is a medical condition in my family that is confirmed to be genetic 
To learn about my genetics because of lack of information about my family history 
There is a medical condition in my family that may be genetic 
To provide disease risk information for my children 
Interest in ancestry 
To learn more about genome sequencing as part of my professional activities 
Desire to plan for the future 
It seemed like it would be fun and entertaining 
Interest in finding out about personal response to medications 
Interest in finding out what I can do to improve my health 
General interest in genetics 
Interest in finding out about personal disease risk 
Curiosity about genetic makeup 
Percent Endorsing Statement
Somewhat important Very important 
26%
31%
32%
35%
41%
45%
7%
10%
9%
13%
16%
15%
0% 20% 40% 60% 80% 100% 
The impact the results might have on my ability to obtain insurance 
The financial cost of having my genome sequenced 
The possibility that I might receive unwanted information 
The privacy of my genetic information 
The complexity of genetic variant interpretation 
How well the results would predict my future disease risk 
Percent Endorsing Statement
Somewhat concerned Very concerned 
a
b Concerns
Motivations
Fig. 2 Motivations and concerns when deciding to pursue personal genome sequencing. a Motivations for pursuing personal genome sequencing.
The light gray indicates the percentage of participants who endorsed the motivation as being somewhat important, and the dark gray indicates the
percentage of participants who endorsed the motivation as being very important. b Concerns participants had when deciding to pursue sequencing.
The light gray indicates the percentage of participants who reported being somewhat concerned about the issue, and the dark gray indicates the
percentage of participants who reported being very concerned about the issue. Motivations and concerns were reported on the pre-disclosure and
catch-up surveys. Percentages are not all based on denominator of 543 because of missing responses to some survey items. The percent of missing
responses ranges between 3.3–23.9% (median = 4.4% missing)
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healthcare provider was unwilling to discuss the mean-
ing of their PPGS results. Dissatisfaction with the discus-
sion of their results was highest for the PGP participants
(12.9% not at all satisfied) and lowest for participants
from the HealthSeq project and YPO and MD/PhD
Genome Projects (0% not at all satisfied), with 6.5% of
UYG participants not at all satisfied with the discussion.
Due to their PPGS results, 12.5% (range 0–17.4% across
projects) of participants reported that they had one or
more tests, medical exams, or procedures, and it was
only in the HealthSeq project that no one reported hav-
ing any tests, medical exams, or procedures because of
their PPGS results. Of those individuals reporting any
tests, exams, or procedures, 13.3% reported undergoing
one or more genetic tests to confirm their PPGS
findings.
Few participants (12.4%) reported making any lifestyle
changes because of their PPGS results: 9.0% and 8.6% re-
ported eating a healthier diet and exercising more, re-
spectively, while less than 1.0% and 0% reported eating a
less healthy diet and exercising less. Less than 1.0% of
participants reported making changes to any of their in-
surance coverage including health, life, long-term care,
and disability insurance.
Decision regret following PPGS results disclosure was
rare with 60.3% of participants reporting no decision re-
gret (score of 0/100) and 95.0% of participants having a
score of 25/100 or less. Fewer than 3.0% of participants
directly reported regretting their decision to pursue
PPGS or experiencing harm due to this decision. When
asked how valuable they felt the PPGS experience was,
88.5% reported that the experience was somewhat
(44.0%) or very (44.5%) valuable. In ranking the per-
ceived utility of their PPGS results on a scale from 1 to
10, participants believed that the information would be
more useful in the future (median = 8.0) than now (me-
dian = 6.0), a statistically significant difference (P <
0.0001). More than one third of participants (39.5%)
somewhat or strongly agreed that they believed they
learned something to improve their health that they did
not know before, and 58.4% somewhat or strongly
agreed that having PPGS made them feel like they had
more control over their health (Table 3). However, more
than half of participants (54.6%) were disappointed that
their PPGS results did not tell them more information.
This was not for lack of understanding, as 79.3% of partic-
ipants agreed that they felt confident that they understood
their PPGS results, which corresponded with an 11-item
genome sequencing knowledge assessment in which >
70% of participants answered 8 of the 11 items correctly.
Almost all participants (96.2%) were somewhat (28.8%) or
very (67.4%) satisfied with their decision to obtain PPGS.
Following PPGS, 84.2% of participants felt somewhat
(25.5%) or very (58.7%) comfortable with the idea of
sharing their entire genome sequence in general. As long
as their identity remained anonymous, over 65% of par-
ticipants across the projects would be willing to share
their entire genome publicly. Most participants were also
in agreement that personal genomic information should
be part of the standard medical record (79.9%) and that
health insurance should cover PPGS (62.8%) (Table 3). A
minority of participants agreed that PPGS should only
be available to people through their doctor (26.6%). Al-
most a quarter of participants (23.4%) both strongly
agreed that personal genomic information should be part
of the medical record and strongly disagreed that se-
quencing should only be available to people through
their doctor.
Table 2 Reported responses following disclosure of genome sequencing results
No. (%)a
Psychological response
Decision regret score, mean (± SD; range)b 6.6 (13.4; 0–100)
Behavioral and medical responses because of sequencing results
Communication of test results
Family 399 (81.1)
Healthcare provider 252 (51.2)
Made appointment with healthcare provider 65 (13.5)
Sought out more information about health or medical topics related to results 237 (48.5)
Made changes to diet 45 (9.4)
Made changes to exercise routine 41 (8.6)
Made changes to medications 29 (7.2)
Made changes to insurance coverage 2 (0.4)
SD standard deviation
aPercentages and means are not all based on total of 543 participants because of missing responses to some survey items. The percent of missing responses
ranges between 8.7 and 25.8% (median = 11.0% missing)
b5-item decision regret scale provides a score from 0 to 100
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Discussion
While an increasing number of healthy individuals are
receiving PPGS results, the balance of benefits, harms, and
downstream costs are still unclear. The PeopleSeq Consor-
tium was formed to systematically collect short- and
long-term medical, behavioral, and economic outcomes of
PPGS. In this report, we have described the design and im-
plementation of the PeopleSeq Consortium surveys, and the
early data from four academic and industry PPGS projects.
Consistent with other PPGS studies, such as the NIH
ClinSeq study [46], and with descriptions of users of
DTC genetic testing [38, 47], most PeopleSeq partici-
pants are white and well-educated with high annual
household incomes. Participants were motivated to
undergo PPGS because of a general curiosity about their
genetic make-up and disease risk, despite considering
themselves to be healthy. Many of these participants had
previously used DTC genetic testing for similar reasons.
These early adopters were also highly knowledgeable
about basic genomics concepts. Unsurprisingly, among
individuals who all chose to undergo PPGS, concerns re-
garding privacy and insurance discrimination, which are
often cited as serious deterrents [48, 49], were modest.
Additionally, strong privacy and insurance discrimin-
ation concerns were lowest for PGP participants whose
genomes were shared publicly, and these concerns were
not relatively high for UYG participants whose clinical
genome reports were sent directly to their physicians.
The PeopleSeq Consortium is a self-selected group of
early adopters of genome sequencing for whom the per-
ceived risks of PPGS were not necessarily a deterrent.
Similarly, in the ClinSeq study, which enrolled
middle-aged adults from the general population who
consented to undergo genome sequencing in a clinical
research setting, participants were found to be high in
dispositional optimism and resilience, personality traits
that could make these individuals more accepting of this
new technology and their genomic information despite
the psychological risks [46]. The risk-taking behavior
and demographics of the PeopleSeq Consortium is char-
acteristic of innovators and early adopters of a new tech-
nology, who are the first to try an innovation and often
provide the evidence needed before adoption by the ma-
jority, as described by the Diffusion of Innovations The-
ory [33]. These characteristics may be most apparent
among participants from PGP who were the least con-
cerned about privacy and insurance discrimination des-
pite their genomic information being made publicly
available online as part of the PGP’s unique approach to
genomic research. [15] While individuals enrolled in
PeopleSeq across all of the projects are clearly
non-representative, the general population also appears
highly receptive to learning about their genomic infor-
mation. As part of focus groups conducted among a
sample of Geisinger patient-participants in establishing
the MyCode® Community Health Initiative, it was re-
ported that a majority of participants were in favor of
the return of genomic results despite possible anxiety or
lack of clinical actionability [21]. In a population-based
sample of U.S. adults surveyed to inform the design of
the PMI’s All of Us Research Program, there was a high
level of willingness to participate in the proposed study,
and most respondents were interested in receiving their
personal health information, including genetic
Table 3 Degree of agreement/disagreement on perceived utility and general attitudes regarding genome sequencing
No. (%)a
Strongly
disagree
Somewhat
disagree
Neither agree nor
disagree
Somewhat
agree
Strongly
agree
Perceived utility of genome sequencing
I learned something to improve my health that I did not know before 70 (14.6) 86 (18.0) 133 (27.8) 105 (22.0) 84 (17.6)
Having personal genome sequencing made me feel like I have more
control over my health
42 (8.7) 44 (9.1) 115 (23.8) 181 (37.5) 101 (20.9)
What I learned from my personal genome sequencing will help reduce
my chances of getting sick
83 (17.2) 104 (21.6) 175 (36.3) 78 (16.2) 42 (8.7)
The information that I received about my genome will influence how I
manage my health in the future
64 (13.3) 50 (10.4) 137 (28.4) 171 (35.5) 60 (12.5)
I am disappointed that my results did not tell me more information 68 (14.2) 63 (13.1) 87 (18.1) 156 (32.5) 106 (22.1)
Attitudes regarding genome sequencing
Personal genomic information should be part of a standard medical
record
7 (1.5) 34 (7.2) 54 (11.4) 152 (32.2) 225 (47.7)
Health insurance should cover personal genome sequencing 26 (5.5) 56 (11.8) 95 (20.0) 128 (26.9) 171 (35.9)
Personal genome sequencing should only be available to people
through their doctor
177 (37.3) 109 (23.0) 62 (13.1) 65 (13.7) 61 (12.9)
aPercentages may not sum to 100 due to rounding. Percentages are not all based on denominator of 543 because of missing responses to some survey items.
The percent of missing responses ranges between 11.0 and 13.1% (median = 11.8% missing)
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information [50]. Despite the apparent enthusiasm from
the general public, these responses may not translate
into actual participation [51]. Thus, while the PeopleSeq
Consortium may not be representative of the larger pop-
ulations that may undergo PPGS in the future, informa-
tion reported by these innovators and early adopters
may provide insights that will inform future policies and
potentially promote wider adoption of the technology.
The outcomes reported by the current users of PPGS
contribute to the evidence needed for (or against) the
utility of sequencing and provide information on the
medical resources that may be necessary as the use of
sequencing expands both commercially and clinically.
The homogenous sociodemographic characteristics of
these early adopters of genome sequencing, who are pre-
dominantly white, wealthy, and well-educated, are similar
to the demographics of innovators and early adopters of
many new technologies [33], but should still be consid-
ered. This Consortium did not provide sequencing but en-
rolled participants who independently sought genome
sequencing through established programs, thus reflecting
the lack of diversity that has long been acknowledged in
the research and genomics community [52–54]. Limited
representation can restrict the possible benefits of genom-
ics in underrepresented ethnic and racial populations due
to greater variant misclassification in these populations,
perpetuating health disparities [52, 55, 56]. These findings
reinforce the need for improved efforts for inclusivity in
research and access to genome sequencing, which is an
aim of the PMI’s All of Us Research Program [57]. The
early adopters in the PeopleSeq Consortium, who are pur-
suing sequencing in its current state, may provide the
much needed data to address the concerns about PPGS,
such as the costs of follow-up care, that may limit partici-
pation by underrepresented groups [54].
After a median of 8 months from disclosure of their
PPGS results, only 13.5% of PeopleSeq participants re-
ported making an additional appointment with a health-
care provider specifically because of their results, and
this was similar across projects despite differences in the
PPGS reports provided. Slightly more than 50% of par-
ticipants, however, reported that they discussed their re-
sults with their healthcare provider, suggesting that most
of these individuals were integrating this information
into their regular care rather than making specific ap-
pointments to do so. These results are consistent with
prior studies of the medical and behavioral impact of
commercial DTC genetic testing of common polygenic
conditions: the PGen Study found that 35% of respon-
dents reported sharing their results with a healthcare
provider [58], and similar proportions were reported in
other DTC genetic testing studies [59, 60]. This is
slightly lower than the 51.2% who reported discussing
their results with a healthcare provider in the current
study, and could be due to differences in the complexity
and scope of results that may be returned with genome
sequencing compared to genetic testing for common
conditions or the role of healthcare providers in order-
ing sequencing in some of the collaborating projects. An
even higher percentage of participants (79.2%) from the
YPO and MD/PhD Genome Projects reported discussing
their results with a healthcare provider compared to the
other projects, and this could be due to more encour-
agement from the study stuff to have these discussions
[17]. While most providers were willing to discuss the
PPGS results, longer follow-up will reveal if and how the
results are integrated into longer-term care and clinical
decision-making. We found some dissatisfaction in par-
ticipants’ discussions about their PPGS results with their
provider, even for participants from UYG which sent
clinical genome reports directly to the ordering pro-
viders. Prior research has revealed that non-geneticist
physicians feel unprepared for sequencing, unsure of
their genomic knowledge and ability to interpret results
[61–63]. A major concern is that the complexities of gen-
ome sequencing could result in a substantial number of
individuals being falsely identified as at-risk for disease [6,
7]. This could create distress or a fatalistic response on the
individual level, iatrogenic harm from unnecessary surveil-
lance or procedures, or overutilization of healthcare re-
sources [9]. Alternatively, individuals without significant
findings may misinterpret those negative results as an in-
dication that they are at no risk, and could have a false
sense of security and not seek appropriate medical care.
Participant-reported personal utility or value of PPGS
was high, with the perceived utility in the future signifi-
cantly outranking current utility. Most participants re-
ported satisfaction with their sequencing experience, and
very few reported any decisional regret. Additionally, al-
most a quarter of participants both strongly agreed that
personal genomic information should be part of the
medical record and strongly disagreed that sequencing
should only be available through a doctor, indicating
comfort with access to sequencing outside of the health-
care system, but a perceived utility of the results for
their medical care. Despite high overall satisfaction with
sequencing, more than half of participants were disap-
pointed that their results did not provide them with
more information, a finding also observed in clinical set-
tings and with DTC genetic testing [64, 65]. These high
expectations of sequencing may reflect a lack of under-
standing of the current capabilities of this technology
and the role of genetics (compared to lifestyle and envir-
onmental factors) on health. Though concerns have
often focused on disclosure of unanticipated findings,
these unrealistically high expectations of genomics
should also be appropriately addressed in advance of
disclosure of genomic results.
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While experts and professional societies recommend
caution around incorporating PPGS into standard clin-
ical practice as a screening tool, sequencing is more eco-
nomically and logistically feasible, and commercial
ventures are responding to public interest by providing
both true DTC, consumer-facing physician mediated,
and traditional provider-mediated genomic products. As
interest in PPGS grows, the need to address the gaps in
our understanding of the implications of PPGS in
healthy individuals becomes more urgent. Results from
the PeopleSeq Consortium thus far do not appear to
support many of the current concerns regarding the
negative consequences of PPGS. Participants reported
feelings of empowerment, and very few reported any dis-
tress or regret after receiving their personal genomic in-
formation. The participants reported sharing their
genomic results with their healthcare providers, and the
Consortium continues to collect data on the medical re-
sponses to quantify the utility or disutility of sequencing.
The strengths of the PeopleSeq Consortium include its
longitudinal design, which allows for the collection of
both short- and long-term outcomes of PPGS, and the
breadth of behavioral and medical data collected. Fur-
thermore, these outcomes are being examined across
both research and commercial PPGS projects that have
not been previously explored in the literature. As the
Consortium is a collaboration of multiple PPGS projects
with different protocols, there is a heterogeneous se-
quencing experience; however, this captures the current
access points of PPGS and enables the exploration of
PPGS experiences across different approaches to the re-
turn of genomic results. These findings then provide a
summary of the outcomes of sequencing across the cur-
rently available means by which individuals can pursue
PPGS. There are limitations to the study. The response
rate is currently below 50%, but methods are being im-
plemented to increase the proportion of responders
moving forward. The results could be affected by nonre-
sponder bias; however, the demographic differences ob-
served between responders and nonresponders, while
statistically significantly different, were not large and
were similar to trends found in other studies of nonre-
sponse [66]. Additionally, we currently do not have in-
formation on the individual genomic results that each
participant received, and responses may vary depending
on the content of the personal genomic reports. Thus,
these findings are a summary of the responses and atti-
tudes of individuals to PPGS results in general. Lastly,
these results may not be generalizable, as early adopters
of PPGS, like innovators and early adopters of most
technologies, are different than the general public [33],
notably being less diverse and potentially having greater
risk-taking tendencies. Yet, little is currently known
about the outcomes or attitudes of anyone undergoing
PPGS and receiving their personal genomic results, and
these individuals are likely to be representative of the in-
novators and early adopters in our society who are shap-
ing the use of genomic technologies and much can be
learned from their experience.
The Consortium is continuing to add additional pro-
jects, enroll additional participants, and administer annual
follow-up surveys beyond the initial results reported on
here. As participants report sequencing-related healthcare
use over time, the associated costs will also be estimated
and evaluated. This will answer questions on the eco-
nomic impact of sequencing in healthy individuals, given
concerns regarding the possible burden of sequencing on
the healthcare system. Furthermore, participants’ genomic
result reports are being collected by the Consortium,
which will provide for rich analyses of outcomes as they
relate to the actual genomic results the participants re-
ceived. Additional strategies are being incorporated to im-
prove the participant response rate and avoid attrition
over longer-term follow-up.
Conclusions
Here we have reported on the design and implementa-
tion of the PeopleSeq Consortium, a collaboration col-
lecting and examining the experiences and medical,
behavioral, and economic outcomes of PPGS in healthy
individuals. These healthy individuals who underwent
predispositional sequencing were not deterred by con-
cerns of privacy of their genomic information or possible
insurance discrimination. Participants were enthusiastic
about their experience and not distressed by their
results. Many participants reported value in their
health-related results, and approximately half reported
discussing their results with a healthcare provider;
though few participants reported making medical or life-
style changes. The participants in the PeopleSeq Consor-
tium are early adopters of PPGS and are providing novel
information on the attitudes and outcomes of current
users of PPGS.
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